Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raju Subramanian

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Bioorganic & Medicinal Chemistry Letters|July 27, 2012
Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffoldRyan P Wurz, Longbin Liu, Kevin Yang, et al.
Journal of Medicinal Chemistry|May 27, 2011
Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivativesNobuko Nishimura, Aaron Siegmund, Longbin Liu, et al.
Antimicrobial Agents and Chemotherapy|June 14, 2021
Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung CellsRuidong Li, Albert Liclican, Yili Xu, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2014
Phosphoinositide-3-kinase inhibitors: evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511Brian A Lanman, Anthony B Reed, Victor J Cee, et al.
Science Translational Medicine|December 30, 2021
Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infectionMeghan S Vermillion, Eisuke Murakami, Bin Ma, et al.
Biorxiv : the Preprint Server for Biology|September 21, 2021
Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in miceAlexandra Schäfer, David R Martinez, John J Won, et al.
Journal of Medicinal Chemistry|February 22, 2011
Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitorsNoel D D'Angelo, Tae-Seong Kim, Kristin Andrews, et al.
Journal of Medicinal Chemistry|April 9, 2021
Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine <i>C</i>-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSVRichard L Mackman, Hon C Hui, Michel Perron, et al.
Journal of Medicinal Chemistry|November 30, 2004
Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channelMark T Bilodeau, Adrienne E Balitza, Timothy J Koester, et al.
Science Translational Medicine|March 22, 2022
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in miceAlexandra Schäfer, David R Martinez, John J Won, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Bioorganic & Medicinal Chemistry Letters|July 27, 2012
Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffoldRyan P Wurz, Longbin Liu, Kevin Yang, et al.
Journal of Medicinal Chemistry|May 27, 2011
Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivativesNobuko Nishimura, Aaron Siegmund, Longbin Liu, et al.
Antimicrobial Agents and Chemotherapy|June 14, 2021
Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung CellsRuidong Li, Albert Liclican, Yili Xu, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2014
Phosphoinositide-3-kinase inhibitors: evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511Brian A Lanman, Anthony B Reed, Victor J Cee, et al.
Science Translational Medicine|December 30, 2021
Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infectionMeghan S Vermillion, Eisuke Murakami, Bin Ma, et al.
Biorxiv : the Preprint Server for Biology|September 21, 2021
Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in miceAlexandra Schäfer, David R Martinez, John J Won, et al.
Journal of Medicinal Chemistry|February 22, 2011
Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitorsNoel D D'Angelo, Tae-Seong Kim, Kristin Andrews, et al.
Journal of Medicinal Chemistry|April 9, 2021
Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine <i>C</i>-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSVRichard L Mackman, Hon C Hui, Michel Perron, et al.
Journal of Medicinal Chemistry|November 30, 2004
Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channelMark T Bilodeau, Adrienne E Balitza, Timothy J Koester, et al.
Science Translational Medicine|March 22, 2022
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in miceAlexandra Schäfer, David R Martinez, John J Won, et al.
Pageof 8